ImetelChat

Ryan, as you may know in addition to using his shoe to pound the podium Kruschev has a special watch constructed (it was nonfunctional) but elicited gasps when he also used this to pound the podium. Thanks for posting, Hoping for that moment too. bp

Hunt, thank you for the encouraging words. I think you may have just succeeded in turning around my world view! bp

Secret third arm, thank you for posting and for representing board interests at the shareholders meeting. I offer my opinion regarding the apparent sparse interest and minimal attendance. I am doing the "brief history of time" quickly from memory so I am sure I have left out many of the failures and...

Bill, I think these are good points. Thanks for posting them. I speculate that Scarlett is searching for the best agent that will be synergistic with Imetelstat. We know that there is a practically linear response that is dose related but toxic levels and untenable side effects are problematic and l...

Kara, I have submitted so many questions for the shareholders meeting that I doubt any additional questions from me will be accepted but you raise some great points and I hope that you (or Cheng) will consider seeking clarification at the meeting. Thanks bp

I am not sdraw but you honor me with the comparison bp

Musings on recent events. IR press releases and conference call: 1. The addition of more former Janssen employees to the team is important and in particular the statistician lends weight to the recent MF abstract. It is clear that the use of "Real World" matched controls takes us away from the priso...

Currently traveling. Will post later re conf call and abstracts. Am struck by the inclusion of a significant p value and a real attempt to establish statistical validly in MF study. Many including myself have suggested Scarlett will avoid a PIII in MF. Using matched controls even though historic, is...

Kara, to clarify re your question about the comparator arm. It was the low dose arm. There was no placebo (i.e. a no drug arm --I wish there had been, if so we would be before the FDA now in my opinion). The value of the comparator arm was not so much that it substituted for a placebo but that it in...

Ryan, yes maybe transfer will be complete but May 16th is the day the EHA abstracts are released. MDS durability may be confirmed and maybe a few more 8 week converters,that ought to do it. Non US partner may be too much to hope for yet. bp

Kara, happy to respond but will wait until after May !6th conference call. That date unlikely to be coincidence sine EHA abstracts will be public then. bp

My personal view is that JS has a strategy with an implied message to FDA that if they don’t approve, even provisionally, on the basis of current data (after all there is 1. A comparitor arm, 2. True unequivocal OS esp in TN 3. Prior well documented CRs/PRs 4. Presumed strong support from thought le...

Kmall, saw your request to make contact directly with Commsman. I will gladly facilitate this once I have his OK, this can be done via PM on board or via SA or YMB. You are really doing a great job of researching and disseminating info. You will probably rate your own Wikipedia entry when you are do...

Gwikley, transfer of the IND is the key and apparently can occur before final data transfer bp

Hunt, read with interest your astute analysis of Dr. Scarlett as CEO in light of an academic view of what does make for a good CEO. Truth is we don't actually know how many hours a day he works for what that looks like but as you imply, it has to be considerable to evaluate possible acquisitions and...

Rinconj, I think it’s pretty clear that imetelstat is trying to carve out “low risk (for aml ), high tx requirement niche. High risk pts you allude to are different, carry a poorer prognosis, and are clearly closer to aml. Since the discussion did not cover that pt population, your answer may lie th...

First off Commisman and Kmall, great stuff, keep up the good work. I do hope some board members can make it to the meeting. I have posted some general questions previously but would like to add a request to get a breakdown as to how the new hires will be utilized, e.g. R and D, manufacturing, admini...

We are starting to see some spam posters, advertisements etc. I will delete any extraneous posts immediately so don't waste your time. If you persist, I will suspend any new registrants and cut you off. Spam is not welcome on this board. bp

This was kindly provided by Hoosier Investor on SA: Hoosier Investor, Contributor Comments619 | Following BP, Conclusion: The International Search Report (ISR) is favorable on the patentability of the combination of Imetelstat + Venetoclax as a treatment for AML. Explanation: Two requirements must b...